
Saturday, July 14, 2018 5:06:09 PM
The biggest mistake novice biotech investors make is falling in love with a novel product that will be hard to sell and/or is going to be difficult for the FDA to approve it, so it burns huge money for years while the company fights with the hospital buyers after a prolonged fight with the ivory tower theorists at the FDA.
VMS is not novel at all and selling will be relatively easy because it is somewhat of a plug and play addition to hospitals existing ultrasound.
https://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00022463
Recent VPTDF News
- Shares Of AI Company Surging On FDA 510(k) Clearance News • AllPennyStocks.com • 02/27/2025 05:55:00 PM
- News Brief: Ventripoint Diagnostics Ltd. • AllPennyStocks.com • 11/20/2024 02:10:00 AM
- Will Shares Rise on Milestone Development for AI-Powered Heart Technology? • AllPennyStocks.com • 05/06/2024 01:50:00 PM
UAV Corp. Successfully Completes Inflation Test of DART SA-70 Airship, Paving Way for Flight Readiness • UMAV • Apr 24, 2025 8:30 AM
InnerScope Hearing Technologies (OTC: INND) Announces the Grand Opening of OTCHealthMart.com • INND • Apr 24, 2025 8:00 AM
Opus Holdings Unveils Powerhouse Leadership Team to Drive Aggressive Growth and Transform Market Trajectory • CATV • Apr 22, 2025 8:30 AM
Glidelogic Corp. (OTCQB: GDLG) Highlights Independent SOTA Evaluation of ResearchMind Platform • GDLG • Apr 22, 2025 6:54 AM
UAV Corp to Launch Inflation Test of SA-70 Airship This Week-A Gateway to High-Value Government and Defense Contracts • UMAV • Apr 21, 2025 1:30 PM
VAYK Corrects Major Clerical Error to Report $668K Operating Revenue for 2024 • VAYK • Apr 17, 2025 9:00 AM